AngioDynamics, Inc. ANGO

AngioDynamics expects its MedTech segment to generate the majority of revenue by fiscal 2027. Projection of MedTech reaching majority revenue signals major strategic shift with potential to reshape company trajectory.

AngioDynamics faces persistent margin pressure despite Med Tech growth, leaving its buy status uncertain amid ongoing operational challenges. Margin pressures offset Med Tech growth and may moderately sway investor views on future performance.

AngioDynamics issued FY27 guidance that spotlights medical technology growth prospects while flagging tariff risks as a key concern for future performance. FY27 guidance directly ties company growth outlook to tariff exposure that can shift financial expectations and investor views.

AngioDynamics held its Q4 2026 earnings call to review financial results, operations, and outlook. Earnings call details key metrics and guidance that directly influence stock valuation and investor positioning.

AngioDynamics, Inc. reported Q4 2026 financial results and provided business outlook during its earnings call. Quarterly earnings and outlook typically affect near-term stock movement and sentiment without altering long-term trajectory.

AngioDynamics Q4 earnings call covered financial results, operational updates, and forward guidance for the medical device company. Q4 earnings call and guidance directly shape near-term stock valuation and investor outlook.

AngioDynamics exceeded revenue forecasts and raised its sales outlook for fiscal 2027. Earnings beat combined with raised guidance signals stronger financial trajectory and positive investor sentiment.

AngioDynamics reported record fiscal 2026 fourth quarter and full year results, with Med Tech segment growth delivering full-year profitability. Record earnings and achieved profitability demonstrate strong execution that will lift revenue trajectory and investor sentiment.

AngioDynamics Inc posted strong Q4 2026 revenue growth despite ongoing challenges. Quarterly revenue figures can shift near-term sentiment but do not signal major strategic or competitive changes.

AngioDynamics reports Q4 loss while beating revenue estimates. Mixed Q4 earnings results typically trigger noticeable but not transformative short-term stock movement.

AngioDynamics reported fiscal Q4 earnings results. Quarterly earnings releases deliver financial metrics that influence near-term investor sentiment and valuation.

AngioDynamics received FDA IDE approval to begin a feasibility study of its NanoKnife system for treating benign prostatic hyperplasia. IDE approval starts early clinical work that may expand NanoKnife use into the BPH market but remains pre-commercial.

AngioDynamics receives FDA IDE approval for RELIEF feasibility study evaluating NanoKnife IRE platform as minimally invasive treatment for benign prostatic hyperplasia. FDA IDE approval enables early-stage evaluation of NanoKnife platform in BPH treatment, supporting moderate future expansion potential.

AngioDynamics expands patient access to NanoKnife IRE for prostate and liver cancer as Medicare coverage framework takes effect. Medicare coverage framework enables broader adoption of NanoKnife IRE for prostate and liver cancer treatments.

AngioDynamics announced two-year PRESERVE trial data demonstrating durable outcomes for the NanoKnife IRE System in treating intermediate-risk prostate cancer. Two-year positive trial data validates NanoKnife efficacy in prostate cancer, likely boosting adoption, revenue, and investor sentiment.

Wall Street analysts predict AngioDynamics (ANGO) stock could surge 64.23%, advising investors to review details before betting. Analyst forecast of 64.23% upside indicates significant potential boost to investor sentiment and market performance.

Wall Street analysts predict AngioDynamics (ANGO) stock could rally 65.75% and outline trading strategies to capitalize on the upside. Analysts' 65.75% rally forecast for ANGO may moderately boost investor sentiment and short-term market performance.

AngioDynamics CEO at Needham Conference touts debt-free turnaround, Auryon market share gains, and NanoKnife launch. Debt-free turnaround, Auryon share gains, and NanoKnife launch represent major financial recovery and product advancements boosting future performance.

AngioDynamics (ANGO) stock rose in pre-market trading after beating Q3 earnings expectations, despite declining gross margins. Q3 earnings beat boosted stock price but gross margin drop tempers overall financial impact.

AngioDynamics Inc (ANGO) reported strong revenue growth in Q3 2026 earnings call highlights, despite financial challenges. Strong revenue growth amid financial hurdles signals significant positive momentum for ANGO's future performance and investor sentiment.

AngioDynamics, Inc. (ANGO) Q3 2026 earnings call summary covers financial results, operational updates, and forward guidance. Q3 2026 earnings call summary details financial performance and strategic outlook with potential to significantly sway investor sentiment and stock trajectory.

AngioDynamics released Q3 earnings call highlights, covering financial results, revenue growth, product updates, and strategic outlook. Q3 earnings highlights reveal financial performance and strategic direction, significantly impacting stock trajectory and investor sentiment.

AngioDynamics reported fiscal year 2026 third quarter financial results, with sustained double-digit med tech growth driving continued profitability. Strong quarterly results with double-digit med tech growth and sustained profitability boost financial trajectory and investor confidence.

AngioDynamics (ANGO) reported a Q3 net loss but exceeded revenue estimates. Q3 loss despite revenue beat affects financial performance and investor sentiment moderately.

Several insiders invested in AngioDynamics, Inc. (ANGO), signaling positive news ahead. Insider buying reflects management confidence, likely boosting short-term market sentiment and stock performance.

AngioDynamics CEO details strategic portfolio shift at conference, with Auryon, AlphaVac, and NanoKnife driving strong growth. CEO-highlighted portfolio shift and growth from Auryon, AlphaVac, and NanoKnife represent major strategic advancements boosting future performance.

AngioDynamics expands indications for the NanoKnife System across Europe, strengthening its multi-organ tumor ablation platform. European indication expansion for NanoKnife significantly broadens market access and revenue potential in tumor ablation.

AngioDynamics, Inc. (ANGO) is projected by Wall Street analysts to potentially increase by 92.15%. The company's recent performance and strategic initiatives have garnered attention, leading to optimistic forecasts regarding its stock value. Analysts are evaluating various factors that could contribute to this anticipated rally, including market trends and company developments. Analysts' projections indicate significant potential for stock appreciation based on strategic initiatives and market conditions.

AngioDynamics, Inc. has partnered with The PERT Consortium® to establish an Investigator-Led Research Fund aimed at enhancing care for patients with pulmonary embolism. This initiative seeks to support innovative research and improve treatment outcomes in this critical area of healthcare. The establishment of a research fund indicates a significant strategic move to enhance AngioDynamics' position in the pulmonary embolism market.

AngioDynamics, Inc. (ANGO) has seen a decline of 3.9% since its last earnings report, raising concerns about its ability to rebound. Analysts are evaluating the company's performance and market conditions to determine potential recovery strategies. Investors are closely monitoring developments that could influence future stock performance. The decline in stock price indicates moderate concerns about financial performance and market sentiment, but no major strategic shifts have been reported.